ER (Estrogen receptor)

This study expands the overlapping morphologic and molecular spectrum of uterine neoplasms resembling uAS showing recurrent fusions (mostly ESR1::NCOA3/2), associated with mostly low-grade histology, lack of heterologous elements and paucity of stromal overgrowth. The nosological relationship of these uAS-like tumors to UTROSCT (driven similarly by ESR1::NCOA3/2 fusions) and to fusion-negative high-grade uAS remains to be verified in future studies utilizing epigenetics and other tools.

These findings indicate that Src plays a crucial role in IFNγ-mediated PD-L1 expression and immune evasion in TNBC cell lines. Src inhibition may represent a promising combinatorial strategy to enhance antitumor immunity in TNBC cell lines.

The existing treatments, such as hormonal drugs and selective estrogen receptor modulators like raloxifene, have side effects and recurrence, and thus indicate the need for less harmful non-hormonal therapies...Procyanidin is a phytochemical lead that shows promise for controlling ESR1 signaling in fibroids and endometriosis as a non-hormonal candidate. Procyanidin emerged as a promising in-silico lead for ESR1 modulation, showing high binding affinity and dynamic stability; nevertheless, further pharmacokinetic, ADMET, and experimental validation are required to substantiate its therapeutic potential.

Hysteroscopic cold knife technology is an effective and minimally invasive treatment for endometrial polyps, with rapid postoperative recovery and protective effects on the endometrium.

In neoadjuvant chemotherapy cohorts, lower ER percentages were associated with greater chemosensitivity, and 14% distinguished response likelihood. These results indicate that continuous ER expression provides prognostic and therapeutic insight beyond current threshold-based classification.

We explore current treatment strategies-including well-known drugs such as Tamoxifen and Fulvestrant, as well as aromatase inhibitors-and explain how these therapies work and why resistance sometimes develops. This article also looks at emerging approaches, like oral estrogen receptor degraders (SERDs), combination therapies, and precision medicine techniques that tailor treatment based on each patient's unique genetic profile. Altogether, these developments represent a major step forward in our understanding and treatment of ER+ breast cancer.

Notably, the combination of Pi-CARM1-TAT with endocrine therapy drugs or etoposide shows synergistic effects in inhibiting breast tumorigenesis. Furthermore, Pi-CARM1-TAT effectively overcomes endocrine therapy resistance in ER-positive breast cancer cells. In conclusion, we present a novel peptide inhibitor of CARM1, which provides valuable insights and may offer therapeutic potential for the development of CARM1-targeted treatments in breast cancer.

Furthermore, naringenin raised serum estradiol and CNS ESRα expression, and its benefits were partially reduced by the ESR antagonist ICI182,780, suggesting ESR signaling contributes to, but does not fully explain, naringenin's immunomodulatory actions. Overall, these findings demonstrate that dietary naringenin ameliorates autoimmune neuroinflammation in an estrogen-deficient EAE model through mechanisms partially dependent on estrogen receptor signaling, supporting its potential as a dietary or adjunctive strategy for MS.

P=N/A, N=75, Recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Dec 2026

Postoperatively, the patient received TC(docetaxel+cyclophosphamide) chemotherapy, total breast irradiation, and tamoxifen for 10 years. Considering the different subtypes and absence of other lesions, the patient was considered to have latent breast cancer as a new lesion. Chemotherapy, including anti- HER2 therapy, radiotherapy, and endocrine therapy, was administered as adjuvant treatment.

Postoperatively, the patient was started on tamoxifen, and she remains recurrence-free to date. This case underscoring the importance of careful pre-treatment assessment of malignancy.